Browsing Tag
RNAi therapy
5 posts
Why Innovent Biologics and SanegeneBio believe IBI3016 could change hypertension treatment
Innovent Biologics and SanegeneBio reveal strong Phase 1 data for IBI3016 at AHA 2025. Discover how this RNAi therapy could redefine hypertension treatment.
Can vutrisiran set a new first-line standard in ATTR-CM after HELIOS-B trial results?
Alnylam’s HELIOS-B data shows vutrisiran cuts GI events by up to 49% in ATTR-CM, reinforcing its case as a first-line therapy. Read the full analysis.
Silexion Therapeutics’ SIL204 emerges as a potential game-changer in KRAS-driven cancer treatment
Silexion Therapeutics (NASDAQ: SLXN) has taken a major step forward in oncology research, unveiling new preclinical data on…
Silexion Therapeutics’ SIL-204 shows potential to transform pancreatic cancer treatment
Silexion Therapeutics Corp. (NASDAQ: SLXN), a clinical-stage biotechnology company specializing in RNA interference (RNAi) therapies, has reported promising…
Silexion Therapeutics’ SIL-204 shows promise in transforming pancreatic cancer treatment
Silexion Therapeutics, a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies, has released compelling preclinical data for its…